[The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia].
OBJECTIVE
To estimate the clinical safety, efficacy of Epristeride in the treatment of benign prostatic hyperplasia (BPH).


METHODS
One hundred and fourty-one BPH patients, aged from 50 to 83 years old [(66.18 +/- 6.41) yr], were given Epristeride tablets 5 mg p.o., twice daily for 120 days. To synthetically estimate the efficacy by the changing rate of international prostate symptom score (IPSS), maximum flow rate (Qmax), the volume of prostate (V) and the residual urine (Ru).


RESULTS
The total efficacy was 81.29%. The adverse reactions include 1 case (0.72%) of exanthem, 1 case (0.72%) of nausea and vomiting, 1 case (0.72%) of insomnia, 1 case (0.72%) of tinnitus and 3 cases (2.16%) of erectile dysfunction. Two patients discontinued the treatment due to the side effects (1.44%). There was no clinical significantly abnormal laboratory index during the treatment.


CONCLUSIONS
Epristeride tablets was safe and effective in the treatment of BPH.
Ju
Xiao-Bing
XB
Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Wu
Hong-Fei
HF
Hua
Li-Xin
LX
Zhang
Wei
W
Li
Jie
J
D000368:Aged; D000369:Aged, 80 and over; D000730:Androstadienes / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D016896:Treatment Outcome
D000730:Androstadienes; C072547:epristeride